Medicalsystem Biotechnology Co., Ltd. (300439.SZ)
CNY 11.1
(-1.16%)
CNY 11.1
(-1.16%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -850.71 Million CNY | -79.18% |
| 2022 | -474.77 Million CNY | -157.41% |
| 2021 | -184.44 Million CNY | -130.82% |
| 2020 | 598.45 Million CNY | -43.88% |
| 2019 | 1.06 Billion CNY | -7.78% |
| 2018 | 1.15 Billion CNY | 41.01% |
| 2017 | 819.98 Million CNY | 450.86% |
| 2016 | 148.85 Million CNY | 130.49% |
| 2015 | -488.28 Million CNY | -6074.5% |
| 2014 | -7.9 Million CNY | 48.77% |
| 2013 | -15.43 Million CNY | -288.25% |
| 2012 | 8.2 Million CNY | 269.01% |
| 2011 | -4.85 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -742.15 Million CNY | 12.76% |
| 2024 Q3 | -567.34 Million CNY | 17.03% |
| 2024 Q2 | -654.13 Million CNY | 11.86% |
| 2023 Q3 | -755.28 Million CNY | -3.61% |
| 2023 FY | -850.71 Million CNY | -79.18% |
| 2023 Q1 | -520.43 Million CNY | -9.62% |
| 2023 Q2 | -728.96 Million CNY | -40.07% |
| 2023 Q4 | -850.71 Million CNY | -12.63% |
| 2022 Q4 | -474.77 Million CNY | -73.06% |
| 2022 FY | -474.77 Million CNY | -157.41% |
| 2022 Q2 | -192.38 Million CNY | -25.35% |
| 2022 Q1 | -153.48 Million CNY | 16.78% |
| 2022 Q3 | -274.34 Million CNY | -42.6% |
| 2021 Q3 | -99.89 Million CNY | -306.56% |
| 2021 Q2 | 48.35 Million CNY | -56.65% |
| 2021 Q1 | 111.56 Million CNY | -81.36% |
| 2021 FY | -184.44 Million CNY | -130.82% |
| 2021 Q4 | -184.44 Million CNY | -84.64% |
| 2020 FY | 598.45 Million CNY | -43.88% |
| 2020 Q4 | 598.45 Million CNY | -26.55% |
| 2020 Q3 | 814.8 Million CNY | -11.75% |
| 2020 Q2 | 923.3 Million CNY | -10.89% |
| 2020 Q1 | 1.03 Billion CNY | -2.82% |
| 2019 Q2 | 1.25 Billion CNY | -1.97% |
| 2019 Q1 | 1.27 Billion CNY | 10.63% |
| 2019 FY | 1.06 Billion CNY | -7.78% |
| 2019 Q4 | 1.06 Billion CNY | -13.73% |
| 2019 Q3 | 1.23 Billion CNY | -1.43% |
| 2018 Q2 | 1.12 Billion CNY | 38.46% |
| 2018 Q1 | 810.61 Million CNY | -1.14% |
| 2018 FY | 1.15 Billion CNY | 41.01% |
| 2018 Q4 | 1.15 Billion CNY | 3.89% |
| 2018 Q3 | 1.11 Billion CNY | -0.84% |
| 2017 FY | 819.98 Million CNY | 450.86% |
| 2017 Q1 | 217.23 Million CNY | 45.94% |
| 2017 Q4 | 819.98 Million CNY | 69.92% |
| 2017 Q3 | 482.58 Million CNY | 243.44% |
| 2017 Q2 | 140.51 Million CNY | -35.32% |
| 2016 Q2 | -70.36 Million CNY | -17.71% |
| 2016 Q4 | 148.85 Million CNY | 45.47% |
| 2016 Q3 | 102.32 Million CNY | 245.42% |
| 2016 Q1 | -59.78 Million CNY | 87.76% |
| 2016 FY | 148.85 Million CNY | 130.49% |
| 2015 Q2 | -698.31 Million CNY | -5267.81% |
| 2015 Q3 | -252.71 Million CNY | 63.81% |
| 2015 Q1 | -13 Million CNY | -64.51% |
| 2015 FY | -488.28 Million CNY | -6074.5% |
| 2015 Q4 | -488.28 Million CNY | -93.21% |
| 2014 Q4 | -7.9 Million CNY | -117.83% |
| 2014 Q1 | 93.43 Million CNY | 0.0% |
| 2014 FY | -7.9 Million CNY | 48.77% |
| 2014 Q3 | 44.35 Million CNY | 0.0% |
| 2013 FY | -15.43 Million CNY | -288.25% |
| 2012 FY | 8.2 Million CNY | 269.01% |
| 2011 FY | -4.85 Million CNY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 1.31 Billion CNY | 164.529% |
| Hangzhou Tigermed Consulting Co., Ltd. | -4.06 Billion CNY | 79.059% |
| Dirui Industrial Co.,Ltd. | -131.62 Million CNY | -546.332% |
| Beijing Strong Biotechnologies, Inc. | 411.59 Million CNY | 306.688% |
| Maccura Biotechnology Co.Ltd | -170.79 Million CNY | -398.097% |
| Guangzhou Wondfo Biotech Co.,Ltd | -240.75 Million CNY | -253.348% |
| Guangdong Hybribio Biotech Co.,Ltd. | -708.27 Million CNY | -20.109% |
| BGI Genomics Co., Ltd. | -3.63 Billion CNY | 76.603% |
| Amoy Diagnostics Co., Ltd. | -92.73 Million CNY | -817.392% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | -486.57 Million CNY | -74.836% |